Edition:
United Kingdom

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
6:35pm GMT
Change (% chg)

$-0.01 (-0.51%)
Prev Close
$1.95
Open
$1.95
Day's High
$1.95
Day's Low
$1.89
Volume
1,683
Avg. Vol
12,496
52-wk High
$5.07
52-wk Low
$1.77

Select another date:

Mon, Nov 13 2017

BRIEF-‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2

* ‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing Source text: [http://bit.ly/2zVA43d] Further company coverage:

BRIEF-‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​

* ‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​ Source text: (http://bit.ly/2yFcZRO) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Soligenix reports Q3 loss per share $0.17

* Soligenix announces recent accomplishments and third quarter 2017 financial results

BRIEF-Soligenix Inc announces pricing of offering

* Soligenix announces pricing of $5,115,000 concurrent registered direct offering and private placement of common stock priced above market

BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​

* Soligenix - ‍national Institutes of Health awarded co about $1.5 million over 2 years to support conduct of pivotal Phase 3 clinical trial evaluating SGX301​ Source text: (http://bit.ly/2yemsz3) Further company coverage:

BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942

* Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer Source text for Eikon: Further company coverage:

BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma

* Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

BRIEF-Soligenix receives $2.5 mln in additional Niaid funding to advance development of heat stable ricin vaccine

* Soligenix receives $2.5m in additional Niaid funding to advance development of heat stable ricin vaccine

BRIEF-Soligenix reports Q2 loss per share $0.41

* Soligenix announces recent accomplishments and second quarter 2017 financial results

BRIEF-Soligenix Inc initiates pivotal phase 3 clinical trial of SGX942

* Soligenix initiates pivotal phase 3 clinical trial of sgx942 (dusquetide) for the treatment of oral mucositis in head and neck cancer patients

Select another date: